Table 2. Results of MLVA and P1 gene types according to macrolide susceptibility and comparison of PSI scores among CAP patients.
| MLVA type | Mpn1 | Mpn13 | Mpn14 | Mpn15 | Mpn16 | Total | P1 gene type | MLs | MLr | PSI scorea | |
| Type I | TypeII | ||||||||||
| B | 2 | 3 | 5 | 6 | 2 | 2 | 0 | 2 | 2 | 0 | NDb |
| E | 2 | 4 | 5 | 7 | 2 | 10 | 10 | 0 | 0 | 10 | 28.1±14.3 |
| G | 3 | 3 | 5 | 6 | 2 | 2 | 0 | 2 | 1 | 1 | ND |
| J* | 3 | 4 | 5 | 7 | 2 | 15 | 15 | 0 | 0 | 15 | 38.9±19.4 |
| K | 3 | 4 | 5 | 6 | 2 | 1 | 1 | 0 | 0 | 1 | ND |
| M | 4 | 3 | 5 | 6 | 2 | 9 | 0 | 9 | 8 | 1 | 25.8±13.1 |
| P | 4 | 4 | 5 | 7 | 2 | 18 | 18 | 0 | 0 | 18 | 24.2±14.5 |
| S | 5 | 3 | 5 | 6 | 2 | 7 | 1 | 6 | 5 | 2 | 28.7±16.8 |
| U** | 5 | 4 | 5 | 7 | 2 | 34 | 34 | 0 | 0 | 34 | 39.4±17.2 |
| V | 6 | 3 | 5 | 6 | 2 | 5 | 0 | 5 | 5 | 0 | 26.4±11.6 |
| X | 6 | 4 | 5 | 7 | 2 | 21 | 21 | 0 | 0 | 21 | 28.1±11.3 |
| Y | 7 | 4 | 5 | 6 | 2 | 1 | 1 | 0 | 0 | 1 | ND |
| Z | 7 | 4 | 5 | 7 | 2 | 5 | 5 | 0 | 0 | 5 | 29.6±21.4 |
| n.c.c | 2 | 4 | 5 | 7 | 3 | 2 | 2 | 0 | 0 | 2 | ND |
| n.c. | 3 | 3 | 5 | 7 | 2 | 1 | 1 | 0 | 0 | 1 | ND |
| n.c. | 3 | 4 | 5 | 7 | 1 | 1 | 1 | 0 | 0 | 1 | ND |
| n.c. | 6 | 4 | 4 | 7 | 2 | 1 | 1 | 0 | 0 | 1 | ND |
| n.c. | 6 | 4 | 5 | 6 | 2 | 1 | 0 | 1 | 1 | 0 | ND |
| Total | 136 | 111 | 25 | 22 | 114 | 32.4±16.1 | |||||
a PSI score (mean ± SD) of corresponding patients.
b ND: not done.
c Not classifiable using the scheme proposed by Degrange et al. (2009).
: J VS M p<0.001, J VS P p = 0.001, J VS S p = 0.008, J VS V p<0.001, J VS X p<0.001, J VS Z p = 0.016;
: U VS E p = 0.031, U VS M p<0.001, U VS P p<0.001, U VS S p<0.001, U VS V p<0.001, U VS X p<0.001, U VS Z p<0.001.